Phaseline

Companies › Getz Pharma

Getz Pharma: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 4, 1 Phase 2, 1 Phase 1; Cardiovascular, Gastroenterology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ertugliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Liver Fat; Heart Failure; Ketones, Metabolism–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05644717ErtugliflozinPhase 4Liver FatGastroenterologyNov 2025
NCT04438213ErtugliflozinPhase 2Heart FailureCardiovascularDec 2025
NCT05662865ErtugliflozinPhase 1Ketones, MetabolismOtherDec 2026

Targets

SLC5A2 (1)

Companies with the same targets

THPharm Boryung Pharmaceutical AstraZeneca Lexicon Pharmaceuticals Boehringer Ingelheim Dong-A ST Hangzhou Zhongmei Huadong Pharmaceutical JW Pharmaceutical

Companies built like this

Dr. F. Köhler Chemie Albireo, an Ipsen Company RHEACELL GmbH & Co. KG Tenax Therapeutics Livzon Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.